Which antipsychotic should you choose? There are dozens of options and approved indications. 

Cobenfy is a novel antipsychotic that acts through the muscarinic acetylcholine system rather than the traditional dopamine pathways.

Tried and true, risperidone’s moderate side effect profile has led to its wide use, and many clinicians consider it their antipsychotic of choice for first-episode psychotic disorders. 

Many consider olanzapine to be more effective than other antipsychotics and just below clozapine in overall efficacy. Its strong effectiveness, once-daily dosing, and low QT-prolongation risk are appealing.

Methadone is a long-acting opioid and a mainstay of opioid use disorder (OUD) treatment.

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder. 

Light therapy is an effective treatment for seasonal affective disorder and possibly for nonseasonal depression as well. 

Pitolisant is the only noncontrolled substance approved for narcolepsy, but limited experience and higher cost make it a second-line option after modafinil and armodafinil.

Solriamfetol is a wakefulness promoter with a different mechanism of action (dopamine and norepinephrine reuptake inhibition) from modafinil and armodafinil.